When we introduced SIGNA™ MAGNUS‡, we embarked on an exploration journey that laid the foundation for groundbreaking neurological discoveries. The FDA-clearance for SIGNA MAGNUS in October 2024, took us one step closer to finding new ways to deal with some of the world’s most complex and deteriorating diseases.
What is even more exciting is that MAGNUS was only the beginning. Today, we are thrilled to unveil our latest MR innovation: SIGNA™ Sprint‡‡. SIGNA Sprint earns its name by embodying our mission to rapidly advance MR capabilities and accessibility for patients throughout the world.
SIGNA Sprint exemplifies two key tenets of our mission: to enable groundbreaking
discoveries while making MR more accessible and sustainable. Bringing an impressive gradient performance for the first time in a 1.5T scanner and native compatibility with our industry-leading AI solutions, SIGNA Sprint is equipped to deliver exceptional power with brilliant intelligence.
Building on the strong foundation of SIGNA MAGNUS, SIGNA Sprint aims to expand MR’s capabilities and applications in two critical care pathways: cardiology and oncology. SIGNA Sprint provides our clinical and academic partners a unique opportunity to tap all the benefits of a 3.0T-like gradient, with the accessibility of a 1.5T system, enabling you to deliver more precise, consistent imaging for patients and research needs. In cardiology, users will recognize the benefits of 1.5T imaging, coupled with impressively short TRs, delivering advanced clinical care made easy. In oncology, users will enjoy ultra-short TEs to reduce distortion in high-resolution diffusion imaging and compatibility with the AIR™ RT Open Coil Suite of surface coils, designed for use with radiation oncology tools.
SIGNA Sprint is more than just an addition to our product lineup – it’s a leap forward in our mission to change the outcome, enabling broader access to the latest technology for more patients and users worldwide.
Together, we are shaping the future of MR imaging, one innovation at a time, so we can leave future generations with a world where healthcare truly has no limits.
‡ SIGNA™ MAGNUS is 510(k) cleared with the FDA. Not yet CE Marked. Not available for sale in all regions.
‡‡ 510(k) pending at US FDA. Not yet CE marked. Not available for sale.
- Previous
- Join us in seeing the future of MR
Continue Reading
The power to explore further
Volume 38 — Spring 2025
Published
AI synergistically transforms the MR experience
Published
Join us in seeing the future of MR
Published
GE HealthCare welcomes new SIGNA Sprint 1.5T to explore further
Published
In partnership with EU consortium, GE HealthCare to advance AI in healthcare through synthetic data
Published
PREDICTOM launches prospective study, gears up for MR protocol harmonization
Published
First modular MR in Southeast Asia
Published
ISMRM 2025 abstracts
Published
MR neurography imaging for all: providing a new service line using existing sequences and systems
Published
Progardia lowers energy consumption, reduces carbon footprint and increases image quality with continued investment in MR and AI
Published
Life-speed imaging with Sonic DL Cine opens up cardiac MR access to those who need it most
Published
Elevating neuro imaging with an upgrade to SIGNA PET/MR
By Ju-Chieh Kevin Cheng, PhD, UBC PET/MRI Physicist, Research Scientist at UBC Pacific Parkinson’s Research Centre, Vesna Sossi, PhD, Professor, Department of Physics and Astronomy, Adjunct Professor at Djavad Mowafaghian Centre for Brain Health, and Elham Shahinfard, PhD, PET-MR Imaging Program Manager, Charles E. Fipke Integrated Neuroimaging Suite, The University of British Columbia, Vancouver, British Columbia, Canada
Published
Advancing women’s imaging through collaboration
Published
The role of deep-learning T2 PROPELLER, diffusion and perfusion sequences in 3.0T MR evaluation of head-neck tumors
By Simona Marzi, PhD, medical physicist, Michele Farella, technologist, Giovanni Di Giulio, technologist, and Antonello Vidiri, MD, Medical Director, Regina Elena National Cancer Institute, Rome, Italy
Published
Leading the way in breast and pelvic imaging with SIGNA Hero
By Shunsuke Matsumoto, MD, Radiology Manager, Keiyu Hospital, Yokohama, Japan
Published
Shorter scan times and higher quality imaging reduce the need for sedation in pediatric patients
By Pär-Arne Svensson, BSc, Research Radiographer MRI, and Liz Ivarsson, MD, Senior Consultant and Pediatric Radiologist, Queen Silvia Children’s Hospital, Gothenburg, Sweden
Published
Enhancing surgical precision and patient outcomes with fMRI
By Yoshiyuki Watanabe, MD, PhD, Professor, Department of Radiology, Shiga University of Medical Science, Ōtsu, Shiga, Japan
Published
Bringing AIR Recon DL to multi-shot diffusion
By Patricia Lan, PhD, MR Scientist, Arnaud Guidon, PhD, Director of Body & Oncology MR, and Suryanarayanan “Shiv” Kauskik, PhD, Senior Digital Product Manager, GE HealthCare
Published
Ultra-high contrast MR of the brain and spinal cord
By Paul Condron, BSc (Hons), MRI Charge Technologist, Mark Bydder, PhD, Senior Research Fellow, Samantha J. Holdsworth, PhD, Executive Director at Mātai Medical Research Institute and Associate Professor at the University of Auckland, Daniel M. Cornfeld, MD, FRANZCR, Clinical Lead, and Graeme M. Bydder, FRANZCR, Scientific Advisory Board Member, Mātai Medical Research Institute, Gisborne, New Zealand
Published
Deuterium metabolic imaging shows promise in detecting Alzheimer’s disease
Published